Novartis
Novartis’ Cosentyx Clinches First Approval for Hidradenitis Suppurativa Treatment
Novartis’ Cosentyx has gained an early lead in the field of hidradenitis suppurativa (HS), a painful skin condition, potentially giving ...
Novartis accuses ex-employee of stealing confidential files for Takeda
Novartis is pursuing legal action against a former employee from its Egyptian affiliate, who is alleged to have taken thousands ...
Novartis’ $3.2B Chinook Investment Soars with Successful Phase 3 Endpoint, Paving the Way for 2024 FDA Filing
Novartis is seeing promising results from its substantial $3.2 billion investment in Chinook Therapeutics. Exciting top-line data from a phase ...
Pluvicto Improves Survival in Earlier Prostate Cancer, But Faces Regulatory Hurdles (ESMO 2023)
ESMO 2023: LBA13 Novartis is eagerly advancing its radiotherapy drug, Pluvicto, with aspirations of its potential in earlier prostate cancer ...
Pfizer gets FDA nod for Lorbrena-Vizimpro combo to treat advanced lung cancer
Pfizer is making strategic moves to reinforce its presence in the oncology arena, with the FDA granting approval for its ...
Novartis halts depression drug trial, putting $210M Cadent buyout at risk
Novartis has made the decision to discontinue a mid-phase program aimed at treating major depressive disorder (MDD) with the investigational ...
Sandoz’s Subdued Market Entrance After Splitting from Novartis
Sandoz has successfully completed its separation from Novartis after extensive preparations lasting over a year. However, the initial valuation on ...
Novartis Explores Possible Sale of Diagnostic Radiopharmaceutical Agents, Reports Bloomberg
Novartis is reportedly exploring the sale of a portion of its diagnostic radiopharmaceutical agents held under the Advanced Accelerator Applications ...
Novartisā iptacopan impresses in phase 3 trial for rare kidney disease
Novartis is celebrating a significant achievement as its investigational oral factor B inhibitor reaches a crucial milestone in a phase ...
Adlai revives Novartisā abandoned cancer drug, raises $57.5M in IPO to fund phase 3 trial
Adlai Nortye has solidified its financial footing, paving the way to determine the fate of its strategic investment in an ...
Novartis Eyes on First-Line Radiotherapy Role for Lutathera Following Triumph in Neuroendocrine Tumors Trial
Over half a decade since its inaugural FDA approval, Novartis is championing promising trial outcomes for Lutathera, positioning it as ...
Novartis gives up on tislelizumab, BeiGeneās PD-1 inhibitor approved in Europe
Novartis has terminated its significant cancer immunotherapy collaboration with BeiGene, ending a partnership that had granted Novartis co-development and co-commercialization ...
Anthosā ABP-959 outperforms Xarelto in preventing bleeding events in phase 2 trial
Blackstone Life Sciences’ substantial $250 million investment in an ex-Novartis drug candidate has yielded yet another positive outcome in its ...
Novartis commissions art exhibition to raise awareness of rare blood cancers
Novartis has taken a creative approach to raise awareness about rare blood cancers, specifically myeloproliferative neoplasms (MPNs), which impact approximately ...
Novartis recalls lot of Sandimmune due to crystal formation in oral solution
Novartis is taking action to recall one lot of its immunosuppressant medication, Sandimmune, due to an unexpected issue with crystallization ...
Novartis drops Gyroscopeās gene therapy for eye disease after disappointing trial results
Novartis is in the process of divesting its eye disease unit, a move that includes discontinuing a geographic atrophy (GA) ...
Novartis sues U.S. government over IRA price negotiations for Entresto
Novartis has taken legal action against the U.S. government in response to the Inflation Reduction Act (IRA), becoming the latest ...
Novartis Unveils Breakthrough Long-Term Data: Leqvio Sustains LDL-C Reduction Beyond Six Years in ESC 2023
In the world of medical innovation, where the quest to tame cardiovascular risk is a relentless endeavor, Novartis unfurls a ...
FDA Approves Novartis’ Tyruko: Revolutionizing MS Treatment Landscape Amidst Legal Drama
Stepping onto the stage with a flourish, Novartis has secured a resounding victory against Biogen in the realm of pharmaceutical ...
Novartis Announces New Round of Layoffs at US Headquarters Following Earlier Job Cuts
Novartis, a Swiss pharmaceutical giant, is set to undergo another round of job cuts at its U.S. headquarters in East ...
Novartis Nears Sandoz Spinoff Milestone with Unique Stock Distribution Strategy
As the long-anticipated spinoff of Novartis’ Sandoz division draws near, the Swiss pharmaceutical giant has unveiled a novel approach to ...
Regulatory Authority Raises Concerns Over Novartis’ Entresto Podcast Marketing Assertions
Novartis, a trailblazer in digital pharma innovation for years, now faces the intricate labyrinth of regulatory compliance. This complex challenge ...
Novartis Acquires Chinook Therapeutics for USD 3.5 Billion to Boost its Renal Portfolio
Novartis, a global pharmaceutical giant, has finalized its deal to buy Chinook Therapeutics, a biotech company that specializes in developing ...
How Remibrutinib, a Novartis Drug, Can Heal Your Hives
Source – Novartis Novartis has unveiled promising initial outcomes from the Phase III REMIX-1 and REMIX-2 trials assessing the effectiveness ...
Novartis Invests $60 Million Upfront in Ionis’ Innovative Cardiovascular Medication
Source – Ionis Pharmaceuticals Novartis has enlisted Ionis to develop another drug for cardiovascular disease, investing $60 million in a ...
Sandoz Plans Biosimilar Technical Development Centre in Slovenia for Future Pipeline Expansion
Source – Novartis July 20, 2023, Sandoz, a renowned global leader in generic and biosimilar medicines, has disclosed a substantial ...
Novartis Acquires DTx Pharma to Boost xRNA Platform and Neuroscience Pipeline
Source – Novartis On July 17, Novartis made an announcement regarding its recent acquisition of DTx Pharma, a biotechnology company ...
Novartis Announces Strong Revenue Growth, Share Buyback, and Sandoz Separation
Source – Novartis Novartis, a pharmaceutical company, has announced a new $15 billion stock repurchase plan after completing a previous ...
After extending its Pfizer collaboration, Samsung Biologics signs a $391M manufacturing agreement with Novartis
Shortly after finalizing two deals worth $897 million with Pfizer, Samsung Biologics has expanded its partnership with Novartis, adding hundreds ...
Novartis to Appeal Court Decision on Entresto Combination Patent; Confirms 2023 Guidance and Mid-Term Outlook
Source: Novartis On July 7, 2023, Novartis received a negative decision from the US District Court regarding the validity of ...
